Vincent Rajkumar, Oncologist at Mayo Clinic specializing in Myeloma, Amyloidosis, Macroglobulinemia, MGUS, and Related Disorders, shared on X:
“First RCT results of Etentamig (BCMA bispecifc antibody) presented at Plenary Session IMS26 Myeloma Society Plasma Cell Pete myelomaMD 60 mg fixed dose every 4 weeks makes this the easiest bispecific to administer.
Impressive PFS benefit in relapsed refractory myeloma with at least 2 prior lines of therapy.
See thread for more details.”
Other articles featuring Vincent Rajkumar on OncoDaily.